Literature DB >> 7532156

Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer.

E Bianchi1, R L Cohen, A Dai, A T Thor, M A Shuman, H S Smith.   

Abstract

We used an immunohistochemical assay with an antigen-retrieval technique to study plasminogen activator inhibitor type-1 (PAI-1) expression in paraffin-embedded breast tissue samples at different stages of malignant transformation. We detected PAI-1 in 15/20 invasive tumors. In several cases staining was localized to the stromal component. PAI-1-positive fibroblasts could be seen surrounding tumor nodules or at tumor margins. In addition, tumor-infiltrating macrophages (13 cases) and endothelial cells (5 cases) were positive. In 11 specimens PAI-1-positive cancer cells were also detected. In 2 strongly positive cases secreted PAI-1 was visible in the extracellular matrix surrounding the cells. Six of 9 samples of carcinoma in situ (DCIS) were weakly positive. No staining of endothelial cells was visible in DCIS. Only a few positive adenomatous epithelial cells could be seen in 3 of 7 papillomas. All biopsies of normal breast tissue were negative, with the exception of one sample, obtained from a patient with a previous segmental mastectomy for DCIS. PAI-1 production by invasive breast cancers could reflect a general upregulation of the plasminogen activation system in proliferating cancer cells, as suggested by the finding that normal mammary epithelium cultures expressed PAI-1 in all cases examined. In addition, production of PAI-1 by the tumor stroma could protect the tumor itself from excessive proteolysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532156     DOI: 10.1002/ijc.2910600505

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.

Authors:  D Albo; D H Berger; J Vogel; G P Tuszynski
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

2.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.

Authors:  E Dublin; A Hanby; N K Patel; R Liebman; D Barnes
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Role of intermediate filaments in migration, invasion and metastasis.

Authors:  M J Hendrix; E A Seftor; Y W Chu; K T Trevor; R E Seftor
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

4.  Regulation of tissue-degrading factors and in vitro invasiveness in progression of breast cancer cells.

Authors:  A H Ree; K Bjørnland; N Brünner; H T Johansen; K B Pedersen; A O Aasen; O Fodstad
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

5.  Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells.

Authors:  G Xiao; Y E Liu; R Gentz; Q A Sang; J Ni; I D Goldberg; Y E Shi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Plasminogen activator inhibitor type 1 interacts with alpha3 subunit of proteasome and modulates its activity.

Authors:  Joanna Boncela; Patrycja Przygodzka; Izabela Papiewska-Pajak; Elzbieta Wyroba; Magdalena Osinska; Czeslaw S Cierniewski
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

7.  Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion.

Authors:  Ming-Tsan Lin; I-Hsin Kuo; Cheng-Chi Chang; Chia-Yu Chu; Hsing-Yu Chen; Been-Ren Lin; Munisamy Sureshbabu; Hou-Jung Shih; Min-Liang Kuo
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

8.  Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.

Authors:  Edson Mantovani Barbosa; Sueli Nonogaki; Maria Lucia Hirata Katayama; Maria Aparecida Azevedo Koike Folgueira; Venâncio Ferreira Avancini Alves; Maria Mitzi Brentani
Journal:  Virchows Arch       Date:  2003-12-02       Impact factor: 4.064

9.  The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.

Authors:  Birgitte Vrou Offersen; Boye Schnack Nielsen; Gunilla Høyer-Hansen; Fritz Rank; Stephen Hamilton-Dutoit; Jens Overgaard; Peter A Andreasen
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

10.  Plasminogen activator inhibitor type 2 in breast cancer.

Authors:  C Duggan; S Kennedy; M D Kramer; C Barnes; P Elvin; E McDermott; N O'Higgins; M J Duffy
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.